Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Achaogen
Achaogen closes series B financing
November 7th, 2006
Achaogen, Inc., a developer of novel antibacterial compounds, announced that it has closed its Series B round of financing, raising over $26 million dollars in a round led by new investor Domain Venture Partners. All of Achaogen's Series A investors (5AM Ventures, ARCH Venture Partners, Venrock Associates, and Versant Ventures) also participated in the Series B round. The company will use the money to advance its lead antibacterial program through clinical proof of concept, and to progress additional programs through preclinical development. "Achaogen has made substantial progress as a company since our start in late 2004," said J. Kevin Judice,...
Source: Drug Law Weekly (2006-11-07)
|
